Pulmonary Arterial Hypertension (PAH) is a progressive, life-threatening disorder characterized by elevated pressure in the pulmonary arteries, leading to right heart failure if untreated.
Hemodynamic Definition
- Mean pulmonary arterial pressure (mPAP) ≥ 20 mmHg
- Pulmonary vascular resistance (PVR) > 2 Wood units
PAH is classified under WHO Group 1 pulmonary hypertension, distinct from other causes such as left heart disease or lung disorders.
Pathophysiology of PAH
PAH results from vascular remodeling and vasoconstriction, driven by:
- Increased endothelin-1 (vasoconstrictor)
- Reduced nitric oxide (vasodilator)
- Impaired prostacyclin pathways
This imbalance leads to:
- Narrowed pulmonary arteries
- Increased vascular resistance
- Progressive right ventricular strain
Causes and Symptoms
PAH can be idiopathic (unknown cause) or associated with other conditions such as connective tissue diseases, congenital heart defects, or chronic liver disease. Common symptoms include shortness of breath (especially during exercise), fatigue, chest pain, dizziness, and swelling in the legs or ankles.
How is PAH Diagnosed?
Diagnosis involves a combination of physical examination, echocardiography, right heart catheterization (the gold standard), and other tests to assess heart and lung function.
Role of Bosentan in PAH Management
Bosentan is a medication classified as an endothelin receptor antagonist (ERA). Endothelin is a substance in the body that causes blood vessels to constrict and promotes cell proliferation, contributing to the narrowing of pulmonary arteries in PAH.
Bosentan works by blocking the effects of endothelin, helping to relax and widen the blood vessels in the lungs. This reduces pulmonary artery pressure and improves blood flow, which can alleviate symptoms, improve exercise capacity, and slow disease progression.
Benefits of Bosentan
- Improves exercise tolerance and quality of life
- Reduces symptoms such as breathlessness and fatigue
- May delay worsening of PAH when used as part of a comprehensive treatment plan
Important Considerations
Bosentan requires regular monitoring due to potential side effects, including liver toxicity and anemia. Patients on bosentan typically undergo periodic liver function tests and blood counts to ensure safety.
Latest Advances in PAH Treatment (2026)
- Early combination therapy strategies
- Personalized treatment based on risk stratification
- New endothelin receptor modulators in trials
Guidance supported by:
- World Health Organization
- National Institutes of Health
Frequently Asked Questions (FAQ)
Is PAH curable?
No, but it is manageable with long-term therapy.
How effective is Bosentan?
It significantly improves symptoms and delays disease progression.
Can bosentan be used in pregnancy?
No, it is strictly contraindicated due to teratogenic effects.
Conclusion
Pulmonary arterial hypertension is a challenging condition, but advances in treatment, including the use of bosentan, have significantly improved patient outcomes. If you or a loved one is diagnosed with PAH, working closely with a healthcare provider specializing in pulmonary hypertension is essential to tailor the best treatment plan.